Cited by 1,102Genomics, phytochemicals, and oxidative stressGlutathione Transferases and PolymorphismsPharmacogenetics and Drug Metabolism

Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice

Open access
Ramos-Gomez, Minerva, Kwak, Mi-Kyoung, Dolan, Patrick M., Itoh, Ken, Yamamoto, Masayuki, Talalay, Paul, Kensler, Thomas W.·2001·Proceedings of the National Academy of Sciences

Abstract

Induction of phase 2 enzymes, which neutralize reactive electrophiles and act as indirect antioxidants, appears to be an effective means for achieving protection against a variety of carcinogens in animals and humans. Transcriptional control of the expression of these enzymes is mediated, at least in part, through the antioxidant response element (ARE) found in the regulatory regions of their genes. The transcription factor Nrf2, which binds to the ARE, appears to be essential for the induction of prototypical phase 2 enzymes such as glutathione S-transferases (GSTs) and NAD(P)H:quinone oxidoreductase (NQO1). Constitutive hepatic and gastric activities of GST and NQO1 were reduced by 50-80% in nrf2-deficient mice compared with wild-type mice. Moreover, the 2- to 5-fold induction of these enzymes in wild-type mice by the chemoprotective agent oltipraz, which is currently in clinical trials, was almost completely abrogated in the nrf2-deficient mice. In parallel with the enzymatic changes, nrf2-deficient mice had a significantly higher burden of gastric neoplasia after treatment with benzo[a]pyrene than did wild-type mice. Oltipraz significantly reduced multiplicity of gastric neoplasia in wild-type mice by 55%, but had no effect on tumor burden in nrf2-deficient mice. Thus, Nrf2 plays a central role in the regulation of constitutive and inducible expression of phase 2 enzymes in vivo and dramatically influences susceptibility to carcinogenesis. Moreover, the total loss of anticarcinogenic efficacy of oltipraz in the nrf2-disrupted mice highlights the prime importance of elevated phase 2 gene expression in chemoprotection by this and similar enzyme inducers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.051618798

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Upregulation of Nrf2-mediated antioxidant proteins renders cancer cells resistant to chemotherapeutic drugs (e.g., cisplatin, 5-fluorouracil, docetaxel, and bortezomib) and radiotherapy.

    “The resultant upregulation of Nrf2-mediated antioxidant proteins renders cancer cells resistant to chemotherapeutic drugs (e.g., cisplatin, 5-fluorouracil, docetaxel, and bortezomib) and radiotherapy [47,161,165,178,179,180,181,182,183,184].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 17

  1. [1]Miller E C, Miller J A. Pharmacol Rev. 1966;18:805–838. [PubMed] [Google Scholar]
  2. [3]Boberg E W, Miller E C, Miller J A, Poland A, Liem M. Cancer Res. 1983;43:5163–5173. [PubMed] [Google Scholar]
  3. [4]Wattenberg L W. Cancer Res. 1985;45:1–8. [PubMed] [Google Scholar]
  4. [7]Richardson H L, Cunningham L. Cancer Res. 1951;11:274. [Google Scholar]
  5. [8]Conney A H, Mueller G C, Miller J A. Cancer Res. 1956;16:450–459. [PubMed] [Google Scholar]
  6. [9]Benson A M, Batzinger R P, Ou S-Y L, Bueding E, Cha Y-N, Talalay P. Cancer Res. 1978;38:4486–4495. [PubMed] [Google Scholar]
  7. [12]Lam L K T, Sparnins V L, Wattenberg L. Cancer Res. 1982;42:1193–1198. [PubMed] [Google Scholar]
  8. [15]Maheo K, Morel F, Langouët S, Kramer H, Le Ferrec E, Ketterer B, Guillouzo A. Cancer Res. 1997;57:3649–3652. [PubMed] [Google Scholar]
  9. [20]Prochaska H J, Talalay P. Cancer Res. 1988;48:4776–4782. [PubMed] [Google Scholar]
  10. [25]Kwak, M.-K., Itoh, K., Yamamoto, M., Sutter, T. R. & Kensler, T. W. (2001) Mol. Med., in press. [PMC free article] [PubMed]
  11. [28]Buetler T, Eaton D L. Cancer Res. 1992;52:314–318. [PubMed] [Google Scholar]
  12. [29]Habig W H, Pabst M J, Jakoby W B. J Biol Chem. 1974;219:7130–7139. [PubMed] [Google Scholar]
  13. [40]Long D J, II, Waikel R L, Wang X-J, Perlaky L, Roop D R, Jaiswal A K. Cancer Res. 2000;60:5913–5915. [PubMed] [Google Scholar]
  14. [44]Primiano T, Egner P A, Sutter T R, Kelloff G J, Roebuck B D, Kensler T W. Cancer Res. 1995;55:4319–4324. [PubMed] [Google Scholar]
  15. [45]Langouët S, Coles B, Morel F, Becquemont L, Beaune P, Guengerich F P, Ketterer B, Guillouzo A. Cancer Res. 1995;55:5574–5579. [PubMed] [Google Scholar]
  16. [47]Gupta E, Olopade O L, Ratain M J, Mick R, Baker T M, Berezin F K, Benson A B., III Clin Cancer Res. 1995;1:1133–1138. [PubMed] [Google Scholar]
  17. [50]Houlston R S. Cancer Epidemiol Biomarkers Prev. 1999;8:675–682. [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W.
Affiliations
  • Departments of Environmental Health Sciences and Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, MD 21205; and Center for TARA, Tsukuba University, Tsukuba 305-8577, Japan
  • Johns Hopkins University (US)
Venue
Proceedings of the National Academy of Sciences
Published
2001-03-13
Volume
98
Issue
6
Pages
3410-3415
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2124524961
Cited by
1,102
References
55
Citations by year
2026: 10 · 2025: 17 · 2024: 29 · 2023: 25 · 2022: 34 · 2021: 25 · 2020: 45 · 2019: 32 · 2018: 26 · 2017: 43 · 2016: 60 · 2015: 52 · 2014: 38 · 2013: 57 · 2012: 64
FWCI
16.41
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Consejo Nacional de Ciencia y Tecnología
  • National Institutes of Health (5p01ca044530-13)
  • National Cancer Institute (CA 44530, CA 39416, R01CA039416)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
Nrf2, antioxidant response element, phase II enzymes, chemoprotection, oltipraz, glutathione S-transferase, NQO1, benzo[a]pyrene, stomach neoplasms, enzyme inducers, Nrf2-deficient mice
MeSH terms
Animals, Benzo(a)pyrene, Carcinogens, Cell Nucleus, Disease Models, Animal, Disease Susceptibility, DNA-Binding Proteins, Epoxide Hydrolases, Female, Genotype, Glutathione Transferase, Mice, Inbred ICR, NADH, NADPH Oxidoreductases, Pyrazines, Stomach Neoplasms, Thiones, Thiophenes, Glucuronosyltransferase, Carcinogenicity Tests, Trans-Activators, Gene Expression, Anticarcinogenic Agents, Mice, Knockout, FMN Reductase, NF-E2-Related Factor 2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review